Synergistic effect of resveratrol and quercetin released from drug-eluting polymer coatings for endovascular devices

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 99 B, Issue 2, 2011, Pages 266-275

  Kleinedler, James J ^a   Foley, John D ^b   Alexander, J Steven ^a   Roerig, Sandra C ^a   Hebert, Valeria Y ^a   Dugas, Tammy R ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Nanocopoeia Inc   (United States)

Author keywords

controlled release polymer coatings; inflammation; polyphenol; restenosis; vascular smooth muscle cells

Indexed keywords

INFLAMMATION; POLYMER COATING; POLYPHENOL; RESTENOSIS; VASCULAR SMOOTH MUSCLE CELLS;

BLOCK COPOLYMERS; BUTENES; CYTOTOXICITY; ENDOTHELIAL CELLS; FATTY ACIDS; MUSCLE; PHENOLS; PLATELETS; POLYMER FILMS; POLYMERS; STAINLESS STEEL; STYRENE;

PLASTIC COATINGS;

QUERCETIN; RESVERATROL;

ARTICLE; BIOCOMPATIBILITY; CELL FUNCTION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED RELEASE FORMULATION; DRUG ACTIVITY; DRUG COATING; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG POTENTIATION; ELECTROSPRAY; HEART ASSIST DEVICE; INFLAMMATORY CELL; LOW DRUG DOSE; MACROPHAGE ACTIVATION; THROMBOCYTE; VASCULAR SMOOTH MUSCLE;

ANTIOXIDANTS; BLOOD PLATELETS; CELL PROLIFERATION; DIFFUSION; DRUG SYNERGISM; DRUG-ELUTING STENTS; HUMANS; INFLAMMATION; KINETICS; MACROPHAGES; MUSCLE, SMOOTH, VASCULAR; NANOCOMPOSITES; PLATELET ACTIVATION; POLYMERS; QUERCETIN; STENTS; STILBENES; VASODILATOR AGENTS;

EID: 80054106734     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.31894     Document Type: Article

References (29)

1. Weintraub WS,. The pathophysiology and burden of restenosis. Am J Cardiol 2007; 100: 3K-9K.
2. Nikol S, Huehns TY, Hofling B,. Molecular biology and post-angioplasty restenosis. Atherosclerosis 1996; 123: 17-31. (Pubitemid 26175066)
3. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R,. Vascular responses to drug eluting stents: Importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27: 1500-1510. (Pubitemid 46986103)
4. Nakazawa G, Finn AV, Virmani R,. Vascular pathology of drug-eluting stents. Herz 2007; 32: 274-280. (Pubitemid 47049609)
5. Ekshyyan VP, Hebert VY, Khandelwal A, Dugas TR,. Resveratrol inhibits rat aortic vascular smooth muscle cell proliferation via estrogen receptor dependent nitric oxide production. J Cardiovasc Pharmacol 2007; 50: 83-93. (Pubitemid 47220451)
6. J G, Cq W, Hh F, Hy D, Xl X, Ym X, By W, Dj H,. Effects of resveratrol on endothelial progenitor cells and their contributions to reendothelialization in intima-injured rats. J Cardiovasc Pharmacol 2006; 47: 711-721.
7. Csiszar A, Smith K, Labinskyy N, Orosz Z, Rivera A, Ungvari Z,. Resveratrol attenuates TNF-alpha-induced activation of coronary arterial endothelial cells: Role of NF-kappaB inhibition. Am J Physiol Heart Circ Physiol 2006; 291: H1694-H1699. (Pubitemid 44497674)
8. Hubbard GP, Wolffram S, Lovegrove JA, Gibbins JM,. Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans. J Thromb Haemost 2004; 2: 2138-2145. (Pubitemid 40185773)
9. Khandelwal AR, Hebert VY, Dugas TR,. Essential role of ER-{alpha}-dependent NO production in resveratrol-mediated inhibition of restenosis. Am J Physiol Heart Circ Physiol 2010; 299: H1451-H1458.
10. Chou TC, Talalay P,. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
11. Dugas TR, Kanz MF, Hebert VY, Hennard KL, Liu H, Santa Cruz V, Conklin D, Boor PJ,. Vascular medial hyperplasia following chronic, intermittent exposure to 4,4′-methylenedianiline. Cardiovasc Toxicol 2004; 4: 85-96.
12. Baydoun AR, Bogle RG, Pearson JD, Mann GE,. Arginine uptake and metabolism in cultured murine macrophages. Agents Actions 1993; 38 Spec No: C127-C1279.
13. Amar S, Oyaisu K, Li L, Van Dyke T,. Moesin: A potential LPS receptor on human monocytes. J Endotoxin Res 2001; 7: 281-286. (Pubitemid 33041065)
14. Tallarida RJ, Stone DJ Jr, Raffa RB,. Efficient designs for studying synergistic drug combinations. Life Sci 1997; 61: PL 417-25.
15. Chen DR, Pui DYH, Kaufman SL,. Electrospraying of conducting liquids for monodisperse aerosol generation in the 4 nm to 1.8 μm diameter range. J Aerosol Sci 1995; 26: 14.
16. van der Woude H, Gliszczynska-Swiglo A, Struijs K, Smeets A, Alink GM, Rietjens IM,. Biphasic modulation of cell proliferation by quercetin at concentrations physiologically relevant in humans. Cancer Lett 2003; 200: 41-47. (Pubitemid 37222357)
17. Peppas NA,. A simple equation for description of solute release I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Control Release 1987; 5: 13.
18. McGillicuddy FC, Lynch I, Rochev YA, Burke M, Dawson KA, Gallagher WM, Keenan AK,. Novel "plum pudding" gels as potential drug-eluting stent coatings: Controlled release of fluvastatin. J Biomed Mater Res A 2006; 79: 923-933. (Pubitemid 44915913)
19. Dong J, Foley JD, Frethem CD, Hoerr RA, Matuszewski MJ, Puskas JE, Haugstad G,. Multimodal dynamic imaging of therapeutic biomedical coatings in aqueous medium. Langmuir 2009; 25: 5442-5445.
20. Peppas NA,. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 1985; 60: 110-111.
21. Welt FG, Rogers C,. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002; 22: 1769-1776. (Pubitemid 35315761)
22. Das S, Alagappan VK, Bagchi D, Sharma HS, Maulik N, Das DK, Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption: A potential mechanism for resveratrol preconditioning of the heart. Vascul Pharmacol 2005; 42: 281-289. (Pubitemid 40726331)
23. Wessely R, Blaich B, Belaiba RS, Merl S, Gorlach A, Kastrati A, Schomig A,. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus.Implications for local drug delivery. Thromb Haemost 2007; 97: 1003-1012. (Pubitemid 46939215)
24. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME,. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231. (Pubitemid 38067635)
25. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME,. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: The TAXUS-IV trial. Circulation 2004; 109: 1942-1947. (Pubitemid 38544483)
26. Storey RF, Chisholm BJ, Masse MA,. Morphology and physical properties of poly(styrene-b-isobutylene-b-styrene) block copolymers. Polymer 1996; 37: 2925-2938. (Pubitemid 126396475)
27. Ranade SV, Miller KM, Richard RE, Chan AK, Allen MJ, Helmus MN,. Physical characterization of controlled release of paclitaxel from the TAXUS Express2 drug-eluting stent. J Biomed Mater Res A 2004; 71: 625-634. (Pubitemid 39578676)
28. Wessely R, Schomig A, Kastrati A,. Sirolimus and Paclitaxel on polymer-based drug-eluting stents: Similar but different. J Am Coll Cardiol 2006; 47: 708-714. (Pubitemid 43243089)
29. Hezi-Yamit A, Sullivan C, Wong J, David L, Chen M, Cheng P, Shumaker D, Wilcox JN, Udipi K,. Impact of polymer hydrophilicity on biocompatibility: Implication for DESs polymer design. J Biomed Mater Res A 2009; 90: 133-141.